Vincerx Pharma Competitors

Vincerx Pharma (NASDAQ:VINC) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Vincerx Pharma and Sigilon Therapeutics, as reported by MarketBeat.

Sigilon Therapeutics has a consensus price target of $53.75, indicating a potential upside of 215.43%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than Vincerx Pharma.

Valuation and Earnings

This table compares Vincerx Pharma and Sigilon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Vincerx Pharma and Sigilon Therapeutics' net margins, return on equity and return on assets.

Summary

Sigilon Therapeutics beats Vincerx Pharma on 2 of the 3 factors compared between the two stocks.

Vincerx Pharma (NASDAQ:VINC) and Inventiva (NYSE:IVA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Profitability

This table compares Vincerx Pharma and Inventiva's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Vincerx Pharma and Inventiva's revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Vincerx Pharma and Inventiva, as provided by MarketBeat.com.

Inventiva has a consensus target price of $27.3333, suggesting a potential upside of 104.59%. Given Inventiva's higher probable upside, analysts plainly believe Inventiva is more favorable than Vincerx Pharma.

Summary

Inventiva beats Vincerx Pharma on 2 of the 3 factors compared between the two stocks.

Vincerx Pharma (NASDAQ:VINC) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Vincerx Pharma and Gemini Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Vincerx Pharma and Gemini Therapeutics' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Vincerx Pharma and Gemini Therapeutics, as provided by MarketBeat.

Gemini Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 95.73%. Given Gemini Therapeutics' higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than Vincerx Pharma.

Summary

Gemini Therapeutics beats Vincerx Pharma on 2 of the 2 factors compared between the two stocks.

Vincerx Pharma (NASDAQ:VINC) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Vincerx Pharma and Landos Biopharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Vincerx Pharma and Landos Biopharma's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Vincerx Pharma and Landos Biopharma, as provided by MarketBeat.

Landos Biopharma has a consensus price target of $25.50, suggesting a potential upside of 121.55%. Given Landos Biopharma's higher possible upside, analysts clearly believe Landos Biopharma is more favorable than Vincerx Pharma.

Summary

Landos Biopharma beats Vincerx Pharma on 2 of the 3 factors compared between the two stocks.

Vincerx Pharma (NASDAQ:VINC) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Vincerx Pharma and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Vincerx Pharma and Terns Pharmaceuticals' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Vincerx Pharma and Terns Pharmaceuticals, as provided by MarketBeat.

Terns Pharmaceuticals has a consensus price target of $30.50, suggesting a potential upside of 70.30%. Given Vincerx Pharma's higher possible upside, equities research analysts clearly believe Vincerx Pharma is more favorable than Terns Pharmaceuticals.

Vincerx Pharma (NASDAQ:VINC) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Valuation & Earnings

This table compares Vincerx Pharma and Sensei Biotherapeutics' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Vincerx Pharma and Sensei Biotherapeutics, as provided by MarketBeat.

Sensei Biotherapeutics has a consensus price target of $29.50, suggesting a potential upside of 108.92%. Given Sensei Biotherapeutics' higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Vincerx Pharma.

Profitability

This table compares Vincerx Pharma and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Summary

Sensei Biotherapeutics beats Vincerx Pharma on 2 of the 2 factors compared between the two stocks.